Andrew J. Armstrong, MD, discusses the updated results and the clinical implications of the final survival analysis of the ARCHES trial, which he coauthored.
Back
Enzalutamide Plus ADT Boosts Survival in mHSPC
Andrew J. Armstrong, MD, MSc, discusses updated data from the phase 3 ARCHES trial (NCT02677896) examining enzalutamide (Xtandi) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, and the clinical implications of the research for this population.
Enzalutamide Plus ADT Boosts Survival in mHSPC
Episodes
All
All
Treatment with the androgen-receptor inhibitor enzalutamide plus androgen deprivation therapy led to significant survival benefits in patients with metastatic hormone-sensitive prostate cancer.
Andrew J. Armstrong, MD, MSc, discusses updated results from the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
3
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
4
Dr Cummings on the Utility of Adjuvant Immunotherapy Alone in Early-Stage NSCLC
5